Fig. 7. NSD2 mediates H3K36me2 modification at BCL2 and SOX2 loci and regulates the extracellular signal–regulated kinase (ERK) and AKT signalling pathways.

a Chromatin immunoprecipitation–quantitative polymerase chain reaction analysis of H3K36me2 enrichment in the BCL2 and SOX2 gene promoters in control and NSD2-KD osteosarcoma (OS) cells. b Venn diagram of the enriched pathways between the indicated groups. c Fourteen pathways shared by circles a, b and c in b. d Western blot analysis of GAPDH, AKT, pAKT, ERK and pERK expression in control and NSD2-KD OS cells with or without cisplatin. e Schematic diagram of the mechanism by which NSD2 mediates OS genesis and chemosensitivity. NSD2 can directly increase H3K36me2 levels at BCL2 and SOX2 loci and activate ERK and AKT signalling pathways to facilitate OS genesis and chemoresistance. *P < 0.05; **P < 0.01